BackMinerva Neurosciences Overview

Minerva Neurosciences Total Current Liabilities

Latest total current liabilities for NERV: $4B.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$3.96B
156415.75% YoYΔ $3.96B vs prior year quarter

Peer average / median

Loading

Minerva Neurosciences Total Current Liabilities History

Loading

Minerva Neurosciences vs. peers: Total Current Liabilities Comparison

Loading

Minerva Neurosciences Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Minerva Neurosciences (NERV) FAQ

Minerva Neurosciences's total current liabilities stands at $4B as of June 2026. That compares with $2.5M in the prior-year period — up 156415.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Minerva Neurosciences reported $4B in total current liabilities versus $2.5M a year earlier — a 156415.7% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $2.5M in the prior-year period — up 156415.7% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Minerva Neurosciences's total current liabilities evolved across reporting periods, while the comparison chart places NERV next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Minerva Neurosciences's reading of $4B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.